country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-187662

Copy Link Print Information

JMX0312

JMX0312 is a small-molecule salicylamide derivative with submicromolar anti-human adenovirus activity, with an IC₅₀ of 0.18 μM. JMX0312 reduces viral loads in the liver and blood and decreases mortality in immunosuppressed hamsters infected with human adenovirus, and it can be used for research on human adenovirus infection.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 439144-75-9
Formel: C₁₄H₈ClF₄NO₂
Molecular Weight:333.67

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

JMX0312 Chemical Structure

CAS. Nr.: 439144-75-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

^[1]

HAdV-5

0.18 μM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
A549	CC₅₀	120.0 μM	Cytotoxicity against A549 cells measured via AlamarBlue assay with 48-hour incubation. Cytotoxicity against A549 cells measured via AlamarBlue assay with 48-hour incubation.	32045239
A549	IC₅₀	2.23 μM	Inhibition of HAdV-5 entry in A549 cells assessed via GFP expression quantification with 48-hour incubation. Inhibition of HAdV-5 entry in A549 cells assessed via GFP expression quantification with 48-hour incubation.	32045239
A549	IC₅₀	0.18 μM	Inhibition of human adenovirus 5 (HAdV-5) replication in A549 cells measured by plaque reduction assay. Inhibition of human adenovirus 5 (HAdV-5) replication in A549 cells measured by plaque reduction assay.	40185285

In Vitro

JMX0312 (compound 17) potently inhibits the plaque formation of HAdV-5 in 293β5 cells, with an IC₅₀ of 0.18 μM; meanwhile, this compound exhibits low cytotoxicity in A549 cells, with a CC₅₀ of 120.0 μM, and thus has a selectivity index as high as 666.7^[1].
JMX0312 (50 μM; 48 h) completely inhibits the entry of HAdV-5 into A549 cells at a concentration of 50 μM. The entry inhibition IC₅₀ in A549 cells is 2.23 μM, and the CC₅₀ is 120.0 μM^[1].
JMX0312 (50 μM) reduces the HAdV-5 viral titer in A549 cells by 989-fold^[1].
JMX0312 (50 μM; 45 min) does not inhibit the delivery of the HAdV-5 genome to the nucleus under the treatment condition of administration at a concentration of 50 μM with continuous action for 45 min during A549 cell infection^[1].
JMX0312 (50 μM; 24 h) does not significantly inhibit HAdV-5 DNA replication in A549 cells when administered at 25 μM for 24 h post-infection^[1].
JMX0312 potently inhibits the replication of HAdV-5 in A549 cells, with an IC₅₀ of 0.18 μM, a CC₅₀ of 120.0 μM, and a selectivity index of 666.7^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Real Time qPCR^[1]

Cell Line:

A549 cells
Concentration:

50 μM
Incubation Time:

45 min
Result:

Showed no significant difference in the amount of nuclear-associated HAdV genomes compared to the DMSO control.

Real Time qPCR^[1]

Cell Line:

A549 cells
Concentration:

50 μM
Incubation Time:

24 h
Result:

Showed low inhibition of HAdV-5 DNA replication compared to the DMSO control.

Parmacokinetics

Species	Dose	Route	C_max	T_1/2	AUC_0-24
Golden hamster^[2]	6.25 mg/kg	i.p.	0.09 mg/L	115.47 min	919.05 mg/min/L

In Vivo

JMX0312 (6.25 mg/kg; i.p.; once daily; for 14 consecutive days) reduces viral loads in the liver and blood of immunosuppressed Syrian hamsters infected with HAdV-C6, and achieves a 14-day survival rate of 50%^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

RjHan/AURA (male, 7 weeks old, ~100 g, immunosuppressed with cyclophosphamide, inoculated with HAdV-C6)^[2]
Dosage:

6.25 mg/kg
Administration:

i.p.; daily; 14 days
Result:

Did not affect animal body weight.
Reduced liver viral load by 3.55 log₁₀ PFU/g to a mean of 7.44 log₁₀ PFU/g in infected animals (dead or euthanized over 14 days).
Reduced blood viral load by 7.49 log₁₀ PFU/mL to a mean of 6.56 log₁₀ PFU/mL in infected animals (dead or euthanized over 14 days).
Achieved a 14-day survival rate of 50%.
Reduced liver viral load to the assay detection limit of 3.5 log₁₀ PFU/g in animals that survived 14 days.
Reduced blood viral load by 3.44 log₁₀ PFU/mL to a mean of 2.67 log₁₀ PFU/mL, just above the assay detection limit of 2.5 log₁₀ PFU/mL, in animals that survived 14 days.

Chemical Information

CAS. Nr. 439144-75-9
Molecular Weight 333.67
Formel C₁₄H₈ClF₄NO₂
SMILES

O=C(C1=CC(Cl)=CC=C1O)NC2=CC(F)=CC(C(F)(F)F)=C2
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Handling Instructions (2659 KB)

Verweise

[1]. Xu J, et al. Structure-Activity Relationship Studies on Diversified Salicylamide Derivatives as Potent Inhibitors of Human Adenovirus Infection. Journal of medicinal chemistry. 2020 Mar 26;63(6):3142-3160. [Content Brief]

[2]. Carretero-Ledesma M, et al. Salicylamide derivative JMX0312 protects immunosuppressed Syrian hamsters against adenovirus lethal challenge. Antiviral research. 2025 Jun;238:106155.

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen